Safety profile following mRNA-1273 COVID-19 primary vaccination in healthy adults in Indonesia
Objectives: To evaluate the safety and benefit-risk profile of mRNA-1273 following the vaccine's authorization and the administration of over one million doses in Indonesia. Design: A retrospective analytical study was conducted to assess adverse events following immunization (AEFI) within 28 days a...
Gorde:
| Egile Nagusiak: | , , , , , , , , , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Elsevier
2026-06-01
|
| Saila: | Global Epidemiology |
| Gaiak: | |
| Sarrera elektronikoa: | http://www.sciencedirect.com/science/article/pii/S2590113326000283 |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|
